-
1Academic Journal
المؤلفون: Alissa M. Michel, Haeseung Yi, Jacquelyn Amenta, Nicole Collins, Anna Vaynrub, Subiksha Umakanth, Garnet Anderson, Katie Arnold, Cynthia Law, Sandhya Pruthi, Ana Sandoval-Leon, Rachel Shirley, Maria Grosse Perdekamp, Sarah Colonna, Stacy Krisher, Tari King, Lisa D. Yee, Tarah J. Ballinger, Christa Braun-Inglis, Debra A. Mangino, Kari Wisinski, Claudia A. DeYoung, Masey Ross, Justin Floyd, Andrea Kaster, Lindi VanderWalde, Thomas J. Saphner, Corrine Zarwan, Shelly Lo, Cathy Graham, Alison Conlin, Kathleen Yost, Doreen Agnese, Cheryl Jernigan, Dawn L. Hershman, Marian L. Neuhouser, Banu Arun, Katherine D. Crew, Rita Kukafka
المصدر: BMC Medical Informatics and Decision Making, Vol 24, Iss 1, Pp 1-15 (2024)
مصطلحات موضوعية: Computer applications to medicine. Medical informatics, R858-859.7
وصف الملف: electronic resource
Relation: https://doaj.org/toc/1472-6947
-
2
المؤلفون: Paul, Weisman, Monica, Ospina-Romero, Qiqi, Yu, Kari, Wisinski, Jin, Xu
المصدر: Pathology - Research and Practice. 238:154087
مصطلحات موضوعية: Cell Biology, Pathology and Forensic Medicine
-
3
المؤلفون: Kari, Wisinski, Ruth, O'Regan
المصدر: Clinical Breast Cancer. 21:95
مصطلحات موضوعية: Cancer Research, Oncology, Humans, Breast Neoplasms, Female, Radiotherapy, Adjuvant, Radiosurgery
-
4
المؤلفون: Madeleine J. Oudin, Oliver Jonas, Tatiana Kosciuk, Liliane Broye, Jeff Wyckoff, Joelle Klazen, John Lamar, Sreeja Asokan, Charlie Whittaker, Robert Langer, Michael Cima, Kari Wisinski, Richard Hynes, Douglas Lauffenburger, Patricia Keely, James Bear, Frank Gertler
المصدر: Cancer Research. 76:B41-B41
مصطلحات موضوعية: Cancer Research, Oncology
-
5Report
المساهمون: Kari Wisinski, Sponsor Investigator
المصدر: A Phase I/II, Single Arm, Non-randomized Study of Ribociclib (LEE011), a CDK 4/6 Inhibitor, in Combination With Bicalutamide, an Androgen Receptor (AR) Inhibitor, in Advanced AR+ Triple-negative Breast Cancer: Big Ten Cancer Research Consortium BRE15-024
-
6Report
المؤلفون: Pfizer, Celcuity Inc
المساهمون: Kari Wisinski, Faculty, University of Wisconsin School of Medicine and Public Health
المصدر: Phase 2 Trial With Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers Big Ten Cancer Research Consortium BTCRC-BRE18-337